Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P. Jackson DJ, et al. Among authors: garcia gil e. Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023. Online ahead of print. Eur Respir J. 2024. PMID: 38575162
Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ, Burhan H, Menzies-Gow A, Pfeffer P, Nanzer A, Garcia Gil E, Morris T, Tran TN, Hirsch I, Dube S. Jackson DJ, et al. Among authors: garcia gil e. J Allergy Clin Immunol Pract. 2022 Jun;10(6):1534-1544.e4. doi: 10.1016/j.jaip.2022.02.014. Epub 2022 Feb 22. J Allergy Clin Immunol Pract. 2022. PMID: 35202871 Free article.
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, Harrison T, Jackson DJ, Price D, Lugogo N, Kreindler J, Burden A, de Giorgio-Miller A, Padilla K, Martin UJ, Garcia Gil E. Menzies-Gow A, et al. Among authors: garcia gil e. Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4. Lancet Respir Med. 2022. PMID: 34619104
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, Harrison T, Jackson DJ, Price D, Lugogo N, Kreindler J, Burden A, de Giorgio-Miller A, Faison S, Padilla K, Martin UJ, Garcia Gil E; PONENTE Study Group. Menzies-Gow A, et al. Among authors: garcia gil e. Eur Respir J. 2022 Dec 22;60(6):2103226. doi: 10.1183/13993003.03226-2021. Print 2022 Dec. Eur Respir J. 2022. PMID: 35896216 Free PMC article.
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.
Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, Dahl Assing K, von Bülow A, Busby J, Cosio BG, FitzGerald JM, Garcia Gil E, Hansen S, aHeaney LG, Hew M, Jackson DJ, Kallieri M, Loukides S, Lugogo NL, Papaioannou AI, Larenas-Linnemann D, Moore WC, Perez-de-Llano LA, Rasmussen LM, Schmid JM, Siddiqui S, Alacqua M, Tran TN, Suppli Ulrik C, Upham JW, Wang E, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Murray RB, Price CA, Price DB. Menzies-Gow AN, et al. Among authors: garcia gil e. J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022. J Asthma Allergy. 2022. PMID: 35046670 Free PMC article.
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy.
Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N, Ariti C, Garcia Gil E, Newell A, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjermer L, Bjerrum AS, Bourdin A, Bulathsinhala L, von Bülow A, Busby J, Canonica GW, Carter V, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtimäki LA, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Sirena C, Papadopoulos N, Papaioannou AI, Pérez de Llano L, Perng DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taillé C, Taube C, Torres-Duque CA, Ulrik CS, Ra SW, Wang E, Wechsler ME, Price DB. Chen W, et al. Among authors: garcia gil e. J Asthma Allergy. 2022 Oct 21;15:1491-1510. doi: 10.2147/JAA.S377174. eCollection 2022. J Asthma Allergy. 2022. PMID: 36303891 Free PMC article.
Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study.
Soremekun S, Heaney LG, Skinner D, Bulathsinhala L, Carter V, Chaudhry I, Hosseini N, Eleangovan N, Murray R, Tran TN, Emmanuel B, Garcia Gil E, Menzies-Gow A, Peters M, Lugogo N, Jones R, Price DB. Soremekun S, et al. Among authors: garcia gil e. Thorax. 2023 Jul;78(7):643-652. doi: 10.1136/thorax-2021-217032. Epub 2022 Aug 3. Thorax. 2023. PMID: 35922128 Free PMC article.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Among authors: garcia gil e. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
64 results